196 related articles for article (PubMed ID: 36321305)
1. C-CAT: The National Datacenter for Cancer Genomic Medicine in Japan.
Kohno T; Kato M; Kohsaka S; Sudo T; Tamai I; Shiraishi Y; Okuma Y; Ogasawara D; Suzuki T; Yoshida T; Mano H
Cancer Discov; 2022 Nov; 12(11):2509-2515. PubMed ID: 36321305
[TBL] [Abstract][Full Text] [Related]
2. [Data-Sharing Systems of the Center for Cancer Genomics and Advanced Therapeutics(C-CAT)Repository Database and Expectation for the Future Medical Research and Development].
Suzuki T
Gan To Kagaku Ryoho; 2022 Nov; 49(11):1175-1182. PubMed ID: 36412016
[TBL] [Abstract][Full Text] [Related]
3. Establishment and implementation of Cancer Genomic Medicine in Japan.
Mukai Y; Ueno H
Cancer Sci; 2021 Mar; 112(3):970-977. PubMed ID: 33289217
[TBL] [Abstract][Full Text] [Related]
4. Cancer genomic medicine in Japan.
Mano H
Proc Jpn Acad Ser B Phys Biol Sci; 2020; 96(7):316-321. PubMed ID: 32788553
[TBL] [Abstract][Full Text] [Related]
5. [Current Status and Future Direction of Cancer Genomic Medicine in Japan].
Muto M
Gan To Kagaku Ryoho; 2020 Feb; 47(2):197-202. PubMed ID: 32381946
[TBL] [Abstract][Full Text] [Related]
6. Cancer genomic medicine in Japan and the roles of pharmacists.
Aomori T; Sakurai H; Nishihara H
Pharmacogenet Genomics; 2022 Aug; 32(6):242-245. PubMed ID: 35696282
[TBL] [Abstract][Full Text] [Related]
7. [Preparation of the Cancer Genomic Medicine in the Tohoku District-Activity of Tohoku University Hospital as the Cancer Genome Medicine Core Base Hospital in Japan].
Ishioka C
Gan To Kagaku Ryoho; 2021 Jul; 48(7):878-881. PubMed ID: 34267020
[TBL] [Abstract][Full Text] [Related]
8. Patient survey on cancer genomic medicine in Japan under the national health insurance system.
Kage H; Akiyama N; Chang H; Shinozaki-Ushiku A; Ka M; Kawata J; Muto M; Okuma Y; Okita N; Tsuchihara K; Kikuchi J; Shirota H; Hayashi H; Kokuryo T; Yachida S; Hirasawa A; Kubo M; Kenmotsu H; Tanabe M; Ushiku T; Muto K; Seto Y; Oda K
Cancer Sci; 2024 Mar; 115(3):954-962. PubMed ID: 38273803
[TBL] [Abstract][Full Text] [Related]
9. [The Role of C-CAT, the Repository Database of Cancer Genomic Medicine in Japan].
Yoshida T
Gan To Kagaku Ryoho; 2019 Apr; 46(4):630-634. PubMed ID: 31164498
[TBL] [Abstract][Full Text] [Related]
10. Current Clinical Practice of Precision Medicine Using Comprehensive Genomic Profiling Tests in Biliary Tract Cancer in Japan.
Kanai M
Curr Oncol; 2022 Sep; 29(10):7272-7284. PubMed ID: 36290850
[TBL] [Abstract][Full Text] [Related]
11. [Panel Discussion - Problems in the Cancer Genomic Medicine].
Ishioka C; Muto M; Yachida S; Shirota H; Hirasawa A; Miyagawa K; Ashizawa K; Kinoshita I; Nishihara H; Matsuura N; Sakurai A
Gan To Kagaku Ryoho; 2022 Sep; 49(9):1014-1017. PubMed ID: 36156030
[TBL] [Abstract][Full Text] [Related]
12. [From the Standpoint of a Core Center Hospital for Cancer Genome Medicine-Establishment of a Provision System for Wide-Area Precision Oncology].
Muto M; Kondo T; Yoshioka M; Fukuyama K; Suga J; Sato M; Masuda F; Ashida K; Mukai K; Matsumoto S; Kanai M
Gan To Kagaku Ryoho; 2021 Jul; 48(7):866-872. PubMed ID: 34267018
[TBL] [Abstract][Full Text] [Related]
13. The initial assessment of expert panel performance in core hospitals for cancer genomic medicine in Japan.
Sunami K; Naito Y; Aimono E; Amano T; Ennishi D; Kage H; Kanai M; Komine K; Koyama T; Maeda T; Morita S; Sakai D; Kohsaka S; Tsuchihara K; Yoshino T
Int J Clin Oncol; 2021 Mar; 26(3):443-449. PubMed ID: 33385275
[TBL] [Abstract][Full Text] [Related]
14. [The Role of Core Hospitals and Cooperative Hospitals for Cancer Genomic Medicine in Japan].
Sunami K
Gan To Kagaku Ryoho; 2019 Apr; 46(4):617-621. PubMed ID: 31164495
[TBL] [Abstract][Full Text] [Related]
15. [Precision Medicine Provided by National Health Insurance].
Muto M; Kondo T; Matsubara J; Kanai M; Matsumoto S; Ashida K; Suga J; Mukai K
Gan To Kagaku Ryoho; 2020 Aug; 47(8):1158-1163. PubMed ID: 32829347
[TBL] [Abstract][Full Text] [Related]
16. Clinical utility of Todai OncoPanel in the setting of approved comprehensive cancer genomic profiling tests in Japan.
Kage H; Shinozaki-Ushiku A; Ishigaki K; Sato Y; Tanabe M; Tanaka S; Tanikawa M; Watanabe K; Kato S; Akagi K; Uchino K; Mitani K; Takahashi S; Miura Y; Ikeda S; Kojima Y; Watanabe K; Mochizuki H; Yamaguchi H; Kawazoe Y; Kashiwabara K; Kohsaka S; Tatsuno K; Ushiku T; Ohe K; Yatomi Y; Seto Y; Aburatani H; Mano H; Miyagawa K; Oda K
Cancer Sci; 2023 Apr; 114(4):1710-1717. PubMed ID: 36601953
[TBL] [Abstract][Full Text] [Related]
17. [The Roles of Designated Core Hospitals and Cooperative Hospitals for Cancer Genomic Medicine in Japan].
Nishida T
Gan To Kagaku Ryoho; 2018 Sep; 45(9):1223-1227. PubMed ID: 30237359
[TBL] [Abstract][Full Text] [Related]
18. The evolution of cancer genomic medicine in Japan and the role of the National Cancer Center Japan.
Yoshida T; Yatabe Y; Kato K; Ishii G; Hamada A; Mano H; Sunami K; Yamamoto N; Kohno T
Cancer Biol Med; 2023 May; 21(1):29-44. PubMed ID: 37133223
[TBL] [Abstract][Full Text] [Related]
19. The Japanese Society of Pathology Practical Guidelines on the handling of pathological tissue samples for cancer genomic medicine.
Hatanaka Y; Kuwata T; Morii E; Kanai Y; Ichikawa H; Kubo T; Hatanaka KC; Sakai K; Nishio K; Fujii S; Okamoto W; Yoshino T; Ochiai A; Oda Y
Pathol Int; 2021 Nov; 71(11):725-740. PubMed ID: 34614280
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of psychological distress, quality of life, and satisfaction among patients and family members following comprehensive genomic profiling testing: Protocol of the Quality of life for Cancer genomics and Advanced Therapeutics (Q-CAT) study.
Nishino M; Fujimori M; Koyama T; Hirata M; Tanabe N; Shimizu T; Yamamoto N; Uchitomi Y
PLoS One; 2023; 18(5):e0283968. PubMed ID: 37235572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
